AbbVie (ABBV) Thursday reported positive topline results from the second Phase 3 UP-AA study evaluating upadacitinib in adult and adolescent patients with severe alopecia areata (AA).
The study met its primary goal by achieving 80% or more scalp hair coverage in 45.2% and 55% of patients treated with upadacitinib 15 mg and 30 mg respectively.
These results were consistent with the previously announced topline results from the first study of Phase 3 UP-AA clinical program.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.